253145-85-6

Basic information

• Product Name: Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-[2-[2-(dimethylamino)eth oxy]ethyl]-5-methyl-
• CAS NO: 253145-85-6
• Molecular Formula: C37H45N3O9
• Molecular Weight: 675.779
• Mol File: 253145-85-6.mol
• Article Data: 83

Chemical Properties

• CAS DataBase Reference: Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-[2-[2-(dimethylamino)eth oxy]ethyl]-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-[2-[2-(dimethylamino)eth oxy]ethyl]-5-methyl-(253145-85-6)
• EPA Substance Registry System: Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-[2-[2-(dimethylamino)eth oxy]ethyl]-5-methyl-(253145-85-6)

Safety Data

• Hazardous Substances Data: 253145-85-6(Hazardous Substances Data)

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 854751-16-9 chloro-bis-(2-methoxy-phenyl)-phenyl-methane 
• 253145-84-5 2'-O-[2-(2-(N,N-dimethylamino)ethoxy)ethyl]-5-methyluridine 
• 1704-62-7 1-O-Dimethylaminoethyl-ethylenglykol 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 40615-39-2 5'-O-(4-4'-dimethoxytrityl)thymidine 

Downstream Products

• 1100804-90-7 5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite 

Relevant articles and documents

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.